ORGO:NASDAQOrganogenesis Holdings Inc. analysis
Data as of Oct 9, 2026 - not real-time
- Latest price
- $1.29
- Risk: high
- 9/10High risk
Summary
At $1.29, Organogenesis Holdings Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 25.9% over the past 30 days. With RSI at 33.0 the momentum picture is approaching oversold, alongside a bullish MACD signal. Recent trading has carved out support near $1.25 and resistance around $1.51.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 55.0% above where the shares trade now. Revenue is contracting at 56.7% on a -18.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 47.4%, a beta of 1.20 and a maximum drawdown of 80.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 55.0% above where the shares trade now. Revenue is contracting at 56.7% on a -18.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 47.4%, a beta of 1.20 and a maximum drawdown of 80.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top market events
- CMS policy changes drove 58% revenue decline, but sequential recovery signals stabilization.
- Organogenesis stock sees no major new catalyst on August 29, 2026, so recent earnings and valuation
- ORGO stock traded at USD 13.67 on September 17, 2026, with a 64.63 percent gain in the cited analysi
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.65
- MACD momentum is positive
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.65
- Analyst targets imply +55.0% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Negative profit margin of -18.4%
- Analyst targets imply +55.0% versus the current price
- Negative return on equity of -25.9%
Key metrics
Financial health
Revenue Growth-56.70%
Profit Margin-18.40%
P/E Ratio-4.2
ROE-25.92%
ROA-4.11%
Debt/Equity23.24
P/B Ratio1.1
Op. Cash Flow$32.0M
Free Cash Flow$28.4M
Industry P/E30.5
Technical analysis
TrendBearish
RSI33.0
Support$1.25
Resistance$1.51
MA 20$1.38
MA 50$1.66
MA 200$2.65
MACDBullish
VolumeIncreasing
Fear & Greed Index94.93
Valuation
Fair Value$2.48
Target Price$2.00
Upside/Downside55.04%
GradeFair
TypeBlend
Risk assessment
Beta1.20
Volatility47.42%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.